News | Coronavirus (COVID-19) | May 21, 2020

RADLogics’ AI-Powered Applications Supporting the Evaluation of COVID-19 Patients are Now Available on Nuance AI Marketplace

Extends access of AI software that supports chest imaging, including CT and X-ray, to U.S. radiologists at over 7,000 healthcare facilities

Extends access of AI software that supports chest imaging, including CT and X-ray, to U.S. radiologists at over 7,000 healthcare facilities

May 21, 2020 — RADLogics announced that its AI-powered medical imaging applications designed to assist in the detection and quantification of findings associated with COVID-19 will now be available on the Nuance AI Marketplace. The Nuance AI Marketplace is the first and largest portal with one-stop access to a wide range of AI diagnostic models from within the industry’s most widely used radiology reporting platform.

Following the announcement of global deployments of RADLogics’ AI-powered devices, the availability of RADLogics’ applications on the Nuance AI Marketplace include patient triage and disease extent measurements, using imaging findings on computed tomography (CT) and X-ray scans. Access to these applications will help meet the growing demand in the U.S. for these solutions that have the capacity to process 1 million CT and 10 million X-rays studies per day through the RADLogics’ cloud-based platform.

RADLogics’ AI-powered software includes algorithms that not only detect abnormalities on chest CTs and X-rays, but also provide automatic triage alerts to the radiologist to help ensure potential findings are reviewed in a timely matter. In addition, the AI-Powered devices provide quantitative analysis of the CT and X-ray images for patients with suspected COVID-19 disease including a score that can help monitor findings over time. In response to the COVID-19 pandemic, RADLogics has dedicated the company’s resources to modify, adapt, and deploy its algorithms to detect lung abnormalities that are compatible with COVID-19 in appropriate clinical settings.

The Nuance AI Marketplace functions like an app store dedicated to radiology. It gives algorithm developers consolidated, at-scale access to users of Nuance PowerScribe™, the radiology reporting system trusted by approximately 80 percent of U.S. radiologists across more than 7,000 connected healthcare facilities. Radiologists can discover, test, and use AI models from within their familiar PowerScribe reporting and worklist workflows to increase reporting efficiency and quality, and to help care teams improve performance and reduce healthcare costs. A built-in feedback channel lets users share real-world results with developers for AI model refinement and post-market surveillance. Hospital systems benefit with simplified purchasing and metrics showing model usage, costs, and performance.

“We are committed to meet the growing demand for our AI-Powered medical imaging analysis solutions during the pandemic by making our applications available to U.S. clinicians and radiology teams through the revolutionary Nuance AI Marketplace,” said Moshe Becker, CEO and Co-Founder of RADLogics. “We are dedicated to supporting the fight against COVID-19, and Nuance’s cloud-based marketplace will facilitate the deployment of our applications to support healthcare systems and providers throughout the U.S. as they continue to treat symptomatic patients.”

In accordance with recent FDA guidance for imaging systems and software to address the COVID-19 public health emergency, RADLogics is committed to making its CT and X-ray solutions available to hospitals and healthcare systems throughout the U.S. for patient triage and management. Designed for easy integration and installation both on-premise and via the cloud – RADLogics’ algorithms are supported by the company’s patented workflow software platform that enables rapid deployment at multiple hospitals, and seamless integration with existing workflows.

For more information: www.radlogics.com

Related Content

Kaplan-Meier curves for all-cause mortality in patients with versus without myocardial injury (Panel A) and in patients with versus without myocardial injury according to the presence or absence of major echocardiographic abnormalities (Panel B). *Includes wall motion abnormalities, global left ventricular dysfunction, diastolic dysfunction, right ventricular dysfunction and presence of pericardial effusion. Event rates are censored at 20 days from hospital admission. Images courtesy of Mount Sinai Health S

Kaplan-Meier curves for all-cause mortality in patients with versus without myocardial injury (Panel A) and in patients with versus without myocardial injury according to the presence or absence of major echocardiographic abnormalities (Panel B). *Includes wall motion abnormalities, global left ventricular dysfunction, diastolic dysfunction, right ventricular dysfunction and presence of pericardial effusion. Event rates are censored at 20 days from hospital admission. Images courtesy of Mount Sinai Health System

News | Ultrasound Imaging | October 28, 2020
October 28, 2020 — Card...
A sonographer at Northwestern Memorial Hospital using the Caption Health AI to optimize ultrasound imaging.

A sonographer at Northwestern Memorial Hospital using the Caption Health AI to optimize ultrasound imaging.

News | Ultrasound Imaging | October 28, 2020
October 28, 2020 — Northwestern Memorial Hospital is the first hospital in the United States to purchase Caption Heal
Radiation Oncology Orchestrator (IntelliSpace Radiation Oncology) and Practice Management can reduce the time from patient referral to the start of treatment by up to half
News | Radiation Oncology | October 25, 2020
October 25, 2020 —Philips, a global leader in health technology, will showcase its latest advances in ...
AI-powered premium large bore CT scanner offers industry’s largest bore and widest field-of-view
News | Computed Tomography (CT) | October 24, 2020
October 24, 2020 — An estimated 1.8 million new cancer cases will be diagnosed in the U.S.
An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone, actually was not flow-limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings.

An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone, actually was not flow-limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings.

Feature | CT Angiography (CTA) | October 23, 2020
October 22, 2020 – In the FORECAST randomized clinical trial, the use of ...
RaySearch Laboratories AB will demo its latest advances in oncology software at the American Society for Radiation Oncology (ASTRO) 2020 Annual Meeting
News | Radiation Oncology | October 23, 2020
October 23, 2020 — RaySearch will present recent and upcoming enhancements, as well as new functionality, in...
A, Initial conventional axial CT image shows no noticeable lung damage (within red box) in right upper lobe. B, Electron density spectral CT image obtained at same time as image in A shows lesions (within red box) in right upper lobe. C, Follow-up conventional axial chest CT image obtained 5 days after images in A and B confirm presence of lesions (within red box) in right upper lobe.

A, Initial conventional axial CT image shows no noticeable lung damage (within red box) in right upper lobe. B, Electron density spectral CT image obtained at same time as image in A shows lesions (within red box) in right upper lobe. C, Follow-up conventional axial chest CT image obtained 5 days after images in A and B confirm presence of lesions (within red box) in right upper lobe. Image courtesy of the American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | October 22, 2020
October 22, 2020 — According to an open-...
The FDA clearance, Quantib’s 6th to date, marks the first time a comprehensive AI prostate solution will be available to radiologists in the United States
News | Prostate Cancer | October 21, 2020
October 21, 2020 — Quantib, a market leader in...